Abbott Laboratories, in Abbott Park, Ill., has received approval of Trilipix (fenofibric acid) delayed-release capsules for use along with diet to help lower triglycerides and LDL and raise HDL in patients with lipid problems.
The drug is the first and only fibrate to be approved for use in combination with a statin. In studies of patients with mixed dyslipidemia, a disorder of all three key lipids affecting millions of American adults, Trilipix used in combination with the most commonly prescribed statins helped manage the three key lipids better than the corresponding therapies alone.
“Only 35% of patients with lipid problems are currently being treated with lipid therapies, and many are not reaching treatment targets for all three key lipids,” said Michael H. Davidson, MD, clinical professor and director of Preventive Cardiology, University of Chicago Pritzker School of Medicine.
“Now Trilipix can be used alone or in combination with a statin to help address lipid problems.” Trilipix has not been shown to prevent heart disease or heart attack.